lyndal hesterberg  barofold inc  zoominfocom   lyndal k hesterberg phd executive profile  biography  bloomberg july    pm et biotechnology company overview of bioptix inc snapshotpeople  overviewboard memberscommittees executive profile lyndal k hesterberg phdconsultant bioptix incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background dr lyndal k hesterberg phd has been senior vice president of research  development board at oncocyte corporation since november   dr hesterberg served as vice president of development at oncocyte corporation from february  to november   dr hesterberg joined oncocyte as a consultant in  he serves as the consultant at venaxis inc he has worked as an industry consultant to medical and biotech companies providing counsel on clinical trial  design product development and corporate strategy he has more than  years of experience in the medical diagnostic and biotechnology industry with a diverse background in research product development and clinical and regulatory successes including k submissions he recruited a senior leadership team that developed a pipeline of proprietary drug candidates and was a director of research executive vice president of scientific affairs and manager of diagnostic product development he served as the head of appyscoretm product development at venaxis inc since august   he founded profoldrx inc in  and served as its chief executive officer and president dr hesterberg served as the chief technology officer of crescendo bioscience inc until  where he was responsible for clinical trial laboratory operations manufacturing and quality systems he joined amgen inc and was part of the team that developed assays for the structure function manufacture and quality control of erythropoietin in  dr hesterberg cofounded biostar inc and served as its executive vice president of scientific affairs and executed a number of corporate partnerships he served as senior director of business development and clinical research services at somalogic inc since november  and was responsible for integrating clinical direction into the development of chipbased proteomics assays he has been a member of advisory board at aegis analytical corporation since december  he served as a director at profoldrx inc he served as a member of advisory board at oncocyte corporation until january   dr hesterberg earned his phd in biochemistry from st louis university and his postdoctoral training as an embo fellow at the max planck institute for biophysical chemistry he holds bachelors of science in biochemistry from the university of illinoisread full background corporate headquarters f south perry streetcastle rock colorado united statesphone fax  board members memberships there is no board members memberships data available education bs university of illinoisurbanachampaignphd saint louis universitypostdoctoral training max planck institute for biophysical chemistry other affiliations aegis analytical corporationuniversity of illinoisurbanachampaignsaint louis universitybarofold incmax planck institute for biophysical chemistrycrescendo bioscience inconcocyte corporation annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact bioptix inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft k premarket notification quick links skip to main page content skip to search skip to topics menu skip to common links us food  drug administration   a to z index follow fda en español enter search terms   home food drugs medical devices radiationemitting products vaccines blood  biologics animal  veterinary cosmetics tobacco products   k premarket notification fda home medical devices databases  k  denovo  registration  listing  adverse events  recalls  pma  hde  classification  standards cfr title   radiationemitting products  xray assembler  medsun reports  clia  tplc   new search back to search results device classification name electrode corneal k number k device name tomey dtl electrode applicant tomey corporation usa  vassar st nd floor cambridge  ma   applicant contact susumu nozawa correspondent tomey corporation usa  vassar st nd floor cambridge  ma   correspondent contact susumu nozawa regulation number classification product code hlz   date received decision date  decision substantially equivalent sese regulation medical specialty ophthalmic k review panel ophthalmic summary summary type traditional reviewed by third party no combination product no   links on this page page last updated  note if you need help accessing information in different file formats see instructions for downloading viewers and players language assistance available español    tiếng việt  한국어  tagalog  русский  العربية  kreyòl ayisyen  français  polski  português  italiano  deutsch    فارسی  english accessibility contact fda careers fda basics foia no fear act site map nondiscrimination website policies us food and drug administration  new hampshire avenue silver spring md  ph infofda  contact fda for government for press combination products advisory committees science  research regulatory information safety emergency preparedness international programs news  events training and continuing education inspectionscompliance state  local officials consumers industry health professionals fda archive   links on this page lyndal k hesterberg  senior vice president research  development at oncocyte corp news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink lyndal k hesterberg senior vice president research  development at oncocyte corp overview in the news relationships paths education career history investments lyndal k hesterberg senior vice president research  development at oncocyte corp overview notable companies barofold inc number of relationships this person is connected to  people in the news see more globenewswire july   oncocyte analytical validation study of its lung cancer diagnostic test confirms previously published results globenewswire november   oncocyte promotes lyndal hesterberg to senior vice president research and development relationships see details adi mohanty director copresident  cochief executive officer at biotime inc william annett chief executive officer president  director at oncocyte corp russell l skibsted chief financial officer  principal accounting officer at biotime inc joseph p wagner former president chief executive officer  director at briacell therapeutics inc william k seltzer vice president of clinical services at oncocyte corp lyssa friedman vice presidentclinical  regulatory affairs at oncocyte corp karen b chapman vice president of research at oncocyte corp kristine c mechem vice presidentmarketing  planning at oncocyte corp william freytag president  chief executive officer at barofold inc robert w peabody chief financial officer at lifemap solutions inc see  more listings with relsci professional start my free trial ➤ see  more paths to lyndal k hesterberg lyndal k hesterberg you connections via relationship science lyndal k hesterberg sync your contacts to see how you can connect with lyndal k hesterberg start my free trial ➤ see more educational background   saint louis university to seek excellence in teaching research health care and service to the community as guided by the spiritual and intellectual ideals of the society of jesus bs biochemistry  university of illinois at urbana  champaign the university of illinois at urbana–champaign is a public researchintensive university in the us state of illinois it is the flagship campus of the university of illinois system the university of illinois at urbana–champaign is the second oldest public university in the state after illinois state university and is a founding member of the big ten conference it is considered a public ivy and is a member of the association of american universities phd biochemistry  st louis university  school of medicine saint louis university school of medicine is a school career history senior vice president research  development   current oncocyte corp oncocyte corp is a pharmaceutical company it is focused on the discovery development and commercialization of novel noninvasive liquid biopsy diagnostics for the early detection of cancer the company was founded in september  and is headquartered in alameda ca head of product development tenure unconfirmed carmenta bioscience inc carmenta bioscience inc provides biotechnology services it offers technology that medical need in maternal and fetal health the company was founded by matthew cooper atul j butte and bruce ling in  and is headquartered palo alto ca chief technology officer    crescendo bioscience inc crescendo bioscience inc develops and commercializes quantitative blood tests for rheumatoid arthritis and other autoimmune diseases it develops quantitative objective reproducible blood tests to provide rheumatologists with deeper clinical insight to help enable more effective management of patients with autoimmune and inflammatory diseases the company was founded by mike b centola and christopher l sutton in july  and is headquartered in south san francisco ca president chief executive officer  founder    barofold inc barofold inc develops and commercializes protein therapeutics the firm applies its pressure enabled protein manufacturing preemt™ technology to improve the tolerability efficacy and safety of protein therapeutics for biopharmaceutical companies research institutions and government agencies it also helps companies create novel protein therapeutics accelerate therapeutic protein development manufacture followon biologics and enable lifecycle management of protein therapeutics the company was founded by matthew seefeldt matthew brewer john f carpenter ted randolph timothy c rodell and lyndal k hesterberg in  and is headquartered in aurora co manager diagnostics    amgen inc amgen inc is a biotechnology medicines company which discovers develops manufactures and markets medicines for grievous illnesses the company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology it markets recombinant protein therapeutics in supportive cancer care nephrology and inflammation the companys products include neulasta a pegylated protein based on the filgrastim molecule and neupogen a recombinantmethionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils enbrel an inhibitor of tumor necrosis factor a substance that plays a role in the bodys response to inflammatory diseases sensiparmimpara a small molecule calcimimetic that lowers serum calcium levels vectibix a monoclonal antibody that binds specifically to the epidermal growth factor receptor and nplate a thrombopoietin receptor agonist that mimics endogenous tpo the primary driver of platelet production amgen was founded by william k bowes jr franklin pitcher johnson jr george b rathmann and joseph rubinfeld on april   and is headquartered in thousand oaks ca director product development    syngen inc syngen inc designs and manufactures innovative devices designed for separation and isolation of therapeutic cells it offers products that improve the recovery purity and viability of stem and other clinically important cells from umbilical cord blood peripheral blood bone marrow and cell culture the firms products include syngenx system cryopro bag sets syngenxlab system and tube welding workstation the company was founded by philip h coelho gabriel g alvarado and george j barry in  and is headquartered in rancho cordova ca headresearch  development prior bioptix inc bioptix inc is a vitro diagnostic company the company focuses on the commercializing of its bloodbased test to serve as an adjunctive test in the diagnosis and treatment of acute appendicitis in children adolescent and young adult patients the company was founded on july   and is headquartered in boulder co senior directorbusiness development prior somalogic inc somalogic inc engages in the development of technologies used in the areas of diagnostics clinical research and pharmaceutical development it offers protein biomarker systems for applications in drug discovery therapeutic treatments and wellness monitoring the firms products and services include somascan service somascan at your institution individual somascan reagents somamer discovery service somalogic clia laboratory and technical support the company was founded by larry gold and david brunel in  and is headquartered in boulder co investments details hidden barofold inc barofold inc develops and commercializes protein therapeutics the firm applies its pressure enabled protein manufacturing preemt™ technology to improve the tolerability efficacy and safety of protein therapeutics for biopharmaceutical companies research institutions and government agencies it also helps companies create novel protein therapeutics accelerate therapeutic protein development manufacture followon biologics and enable lifecycle management of protein therapeutics the company was founded by matthew seefeldt matthew brewer john f carpenter ted randolph timothy c rodell and lyndal k hesterberg in  and is headquartered in aurora co other affiliations lyndal k hesterberg is affiliated with oncocyte corp carmenta bioscience inc crescendo bioscience inc barofold inc amgen inc syngen inc bioptix inc somalogic inc youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ oncocyte  promotes lyndal hesterberg to senior vice president research and development  traders log in email password remember forgot password  become a member for free sign up sign up new membersign up for free new customerdiscover our portfolios united states united kingdom france deutschland schweiz de suisse fr settings dynamic quotes  offon markets equities north americaeuropeasiaoceaniamiddle east» more equities indexes dow jonessp nasdaq tsx compftse » more indexes currency  forex eur  usdgbp  usdusd  jpyusd  cadaud  usd» more currencies commodities goldcrude oil wticrude oil brentsilverplatinum» more commodities news latest news companiesmarketseconomycurrency  forexcommoditiesinterest ratesbusiness leadersfinancial calendareconomic calendar listed company analyst recorumorsiposcapital markets transactionsnew contractsprofits warningsappointmentspress releaseseventscorporate actions sector news energybasic materialsindustrialsconsumer cyclicalconsumer noncyclicalfinancialshealthcaretechnologytelecommunications servicesutilities analysis all analysiscommentariesindex analysisstock trading strategiescommodity analysisforex analysis stock picks all stock picks portfolios my portfolio virtual portfolios traders portfolios european portfoliousa portfolioasian portfolio screeners market screener homefundamental analyse top investor ratingtop trading ratingtop consensusgrowth stocksyield stockslow valuations technical analysis oversold stocksoverbought stocksclose to resistancesclose to supportsaccumulation phasemost volatile stocks watchlists my watchlists watchlists top lists yield stocksgrowth stocksundervalued stocks top  flop top news most read newshot news top fundamentals top capitalizationtop yieldtop pertop consensustop fundamentals top technicals top rsiunusual volumestop gapstop stim top movers top usatop canadatop uktop germanytop europetop asia tools market screenerdynamic chartfinancial calendareconomic calendarsector researchcurrency converter our services premium accessdiscover our services traders homepage    equities    nyse mkt    oncocyte corp    ocx oncocyte corp ocx add to my list    mes dernières consultmost popular manage my lists  delayed     pm  usd     oncocyte  receives  million in proceeds from exercise of warra  oncocyte to report second quarter financial results on august   oncocyte  ocx completes analytical validation study of its lung ca summaryquoteschartsnewsanalysiscalendarcompanyfinancialsconsensusrevisions news summarymost relevantall newssector newstweets oncocyte  promotes lyndal hesterberg to senior vice president research and development    am cest send by mail  last name  name  from  to  you can enter multiple email addresses separated by commas message  required fields globenewswire  oncocyte corporation nyse mktocx a developer of novel noninvasive bloodbased tests for the early detection of cancer today announced that lyndal hesterberg phd has been promoted to senior vice president research and development a newly created position reporting to william annett oncocytes chief executive officer in his new role dr hesterberg will oversee the companys research development clinical and regulatory teams dr hesterberg joined oncocyte as a consultant in  and was named vice president of development in february of  he has worked extensively as an industry consultant to medical and biotech companies providing counsel on clinical trial design product development and corporate strategy during his career he has helped bring to market many diagnostic products via both the fda and laboratory developed test regulatory pathways dr hesterberg was the chief technical officer at crescendo biosciences where he was responsible for clinical trials laboratory operations manufacturing and quality systems and helped bring to market vectra da prior to that he was the president and ceo of barofold inc where he led the company from product conception through its clinical stage he also has served as a founder and evp of scientific affairs at thermo biostar director of product development at syngene and manager of diagnostic product development at amgen he received his phd in biochemistry from the university of st louis and a bachelor of science from the university of illinois lyndals contribution to our rd efforts are invaluable and he is spearheading the development of our lung cancer test commented mr annett this newlycreated position will focus our rd organizational structure as we move towards the potential launch of our lung cancer diagnostic test in the second quarter of  i am confident that lyndals industry expertise and success bringing products to market will enable him to excel in this role i continue to be impressed with the depth of oncocytes science and robust product development pipeline commented dr hesterberg i look forward to continued progress towards launching our lung cancer diagnostic test and to the development of other tests such as one for breast cancer about oncocyte corporationoncocyte is primarily focused on the development and commercialization of novel noninvasive blood and urine liquid biopsy diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses to reduce the cost of care through the avoidance of more costly diagnostic procedures including invasive biopsy and cystoscopic procedures and to improve the quality of life for cancer patients while current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant oncocyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples oncocytes pipeline products are intended to be confirmatory diagnostics for detecting lung bladder and breast cancer oncocytes diagnostic tests are being developed using proprietary sets of genetic and protein markers that differentially express in specific types of cancer forward looking statementsany statements that are not historical fact including but not limited to statements that contain words such as will believes plans anticipates expects estimates and similar expressions should also be considered to be forwardlooking statements these statements include those pertaining to the implementation and results of our validation study and other studies commercialization plans future financial andor operating results future growth in research technology clinical development and potential opportunities for oncocyte along with other statements about the future expectations beliefs goals plans or prospects expressed by management forwardlooking statements involve risks and uncertainties including without limitation risks inherent in the development andor commercialization of potential diagnostic tests or products uncertainty in the results of clinical trials or regulatory approvals the need and ability to obtain future capital and maintenance of intellectual property rights and the need to obtain third party reimbursement for patients use of any diagnostic tests we commercialize actual results may differ materially from the results anticipated in these forwardlooking statements and as such should be evaluated together with the many uncertainties that affect the business of oncocyte particularly those mentioned in the risk factors and other cautionary statements found in oncocytes securities and exchange commission filings oncocyte disclaims any intent or obligation to update these forwardlooking statements except as required by law investor contact evc group inc michael polyviou  mpolyviouevcgroupcom media contact thomas gibson  tomtomgibsoncommunicationscomc all kuna right are reserved  provided by syndigate media inc syndigateinfo source middle east  north african newspapers  latest news on oncocyte corp  oncocyte corp  unregistered sale of equity securities regulation fd disclosure  oncocyte  receives  million in proceeds from exercise of warrants  oncocyte to report second quarter financial results on august    oncocyte  ocx completes analytical validation study of its lung cancer diagnos  oncocyte  analytical validation study of its lung cancer diagnostic test confir  oncocyte  title oncocyte receives  million in proceeds from exercise of wa  oncocyte receives  million in proceeds from exercise of warrants  oncocyte analytical validation study of its lung cancer diagnostic test confi  oncocyte  title oncocyte corporation added to russell ® index and russell   oncocyte corporation added to russell ® index and russell ® index more news news from seekingalpha  when is invitae diagnosed as oversold  oncocytes ocx ceo bill annett discusses data from the  patient rd vali  oncocytes bloodbased lung cancer test  sensitive market launch planned   biotime inc  sifting through numerous trials for potential opportunities  oncocyte misses by  financials  sales   m ebit   m net income   m finance   m yield   pe ratio   pe ratio  ev  sales   x ev  sales  x capitalization  m more financials chart oncocyte corp duration  auto  months  months  months  months  year  years  years  years max period  day week fullscreen chart income statement evolution please enable javascript in your browsers settings to use dynamic charts more financials consensus sell buy mean consensus buy number of analysts  average target price   spread  average target  consensus details eps revisions please enable javascript in your browsers settings to use dynamic charts more estimates revisions managers nametitlewilliam annett president chief executive officer  director alfred dennis kingsley executive chairman russell l skibsted chief financial  accounting officer william k seltzer vice presidentclinical services lyndal k hesterberg senior vice presidentresearch  development more about the company sector and competitors st jancapitalization m oncocyte corp amgen  celgene corporation  gilead sciences  regeneron pharmaceuticals  vertex pharmaceuticals  more results traderscom marketsnewsanalysisstock picksportfoliosscreenerswatchliststop  floptoolsour servicesabout surperformance sascontact usadvertiselegal informationsabout usstay connected facebooktwitterpartners börse aktien kurse und nachrichtenbest tweets copyright   surperformance all rights reserved slave